Cantor Fitzgerald Weighs in on Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Ardelyx in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biopharmaceutical company will earn ($0.13) per share for the year. The consensus estimate for Ardelyx’s current full-year earnings is ($0.17) per share.

ARDX has been the topic of a number of other research reports. HC Wainwright restated a “neutral” rating and set a $5.50 price objective on shares of Ardelyx in a research report on Thursday, January 16th. Citigroup reduced their price target on Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, Jefferies Financial Group cut their target price on shares of Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, January 2nd. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.25.

Ardelyx Stock Performance

Shares of Ardelyx stock opened at $4.91 on Wednesday. The company’s 50 day moving average price is $5.15 and its two-hundred day moving average price is $5.65. The firm has a market capitalization of $1.16 billion, a P/E ratio of -16.37 and a beta of 0.85. Ardelyx has a fifty-two week low of $4.32 and a fifty-two week high of $10.13. The company has a debt-to-equity ratio of 0.64, a current ratio of 4.03 and a quick ratio of 3.87.

Insider Buying and Selling at Ardelyx

In other news, CEO Michael Raab sold 25,000 shares of Ardelyx stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $5.91, for a total transaction of $147,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,210,108 shares in the company, valued at $7,151,738.28. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Justin A. Renz sold 5,260 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.79, for a total value of $25,195.40. Following the completion of the sale, the chief financial officer now directly owns 291,139 shares of the company’s stock, valued at approximately $1,394,555.81. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 218,358 shares of company stock valued at $1,189,516. Corporate insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

Several institutional investors have recently added to or reduced their stakes in the stock. Coastal Bridge Advisors LLC purchased a new stake in Ardelyx during the second quarter valued at about $74,000. Helen Stephens Group LLC purchased a new stake in shares of Ardelyx during the 3rd quarter valued at approximately $76,000. CWM LLC boosted its holdings in Ardelyx by 328.1% in the 3rd quarter. CWM LLC now owns 12,814 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 9,821 shares during the period. Algert Global LLC purchased a new position in Ardelyx in the 2nd quarter valued at approximately $174,000. Finally, Aigen Investment Management LP lifted its position in shares of Ardelyx by 29.4% during the third quarter. Aigen Investment Management LP now owns 23,510 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 5,346 shares in the last quarter. Institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.